Brief: Merus Reports Publication In Nature Cancer On Petosemtamab's Unique Mechanism Of Action
25/04/2022 13:03
April 25 (Reuters) - Merus NV MRUS.O :
* MERUS ANNOUNCES PUBLICATION IN NATURE CANCER ON
PETOSEMTAMAB'S
(MCLA-158) UNIQUE MECHANISM OF ACTION
* MERUS NV - MERUS IS PLANNING A CLINICAL UPDATE FOR SECOND
HALF
OF 2022
Source text for Eikon: ID:nGNXbTvQKF
Further company coverage: MRUS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merus NV
See all newsNASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab